Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal foam refers to the presence of gas bubbles within the digestive tract, often observed as foamy or frothy stool. These gas bubbles are collections of gases—primarily carbon dioxide, oxygen, nitrogen, hydrogen, and sometimes methane—trapped in mucus or liquid within the gastrointestinal lumen. The formation of such foam is typically a result of either increased gas production or impaired absorption/elimination. It is often an indicator of underlying disturbances such as malabsorption syndromes, infections, pancreatic insufficiency, irritable bowel syndrome (IBS), or dietary factors. Simethicone can provide symptomatic relief.
Anti-foaming agent; reduces surface tension to coalesce small gas bubbles into larger, more easily expelled bubbles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal Foam (Gas Bubbles) (N/A).